IL241558B - Improved preparations for the treatment of muscular dystrophy - Google Patents
Improved preparations for the treatment of muscular dystrophyInfo
- Publication number
- IL241558B IL241558B IL24155815A IL24155815A IL241558B IL 241558 B IL241558 B IL 241558B IL 24155815 A IL24155815 A IL 24155815A IL 24155815 A IL24155815 A IL 24155815A IL 241558 B IL241558 B IL 241558B
- Authority
- IL
- Israel
- Prior art keywords
- muscular dystrophy
- improved compositions
- treating muscular
- treating
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793463P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029610 WO2014144978A2 (en) | 2013-03-15 | 2014-03-14 | Improved compositions for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL241558B true IL241558B (en) | 2019-10-31 |
Family
ID=50678303
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL24155815A IL241558B (en) | 2013-03-15 | 2015-09-10 | Improved preparations for the treatment of muscular dystrophy |
| IL26984519A IL269845A (en) | 2013-03-15 | 2019-10-06 | Improved preparations for the treatment of muscular dystrophy |
| IL278912A IL278912A (en) | 2013-03-15 | 2020-11-23 | Improved preparations for the treatment of muscular dystrophy |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL26984519A IL269845A (en) | 2013-03-15 | 2019-10-06 | Improved preparations for the treatment of muscular dystrophy |
| IL278912A IL278912A (en) | 2013-03-15 | 2020-11-23 | Improved preparations for the treatment of muscular dystrophy |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US9506058B2 (enExample) |
| EP (2) | EP3662912B1 (enExample) |
| JP (2) | JP2016516066A (enExample) |
| KR (2) | KR20150133768A (enExample) |
| CN (2) | CN113633787A (enExample) |
| AU (3) | AU2014233456B2 (enExample) |
| BR (1) | BR112015022998A2 (enExample) |
| CA (1) | CA2906812A1 (enExample) |
| EA (1) | EA201591792A1 (enExample) |
| HK (1) | HK1220154A1 (enExample) |
| IL (3) | IL241558B (enExample) |
| MX (2) | MX373959B (enExample) |
| NZ (2) | NZ732507A (enExample) |
| WO (1) | WO2014144978A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| TR201902952T4 (tr) | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| MX373959B (es) | 2013-03-15 | 2020-07-13 | Sarepta Therapeutics Inc | Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd). |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| MX388743B (es) | 2015-05-19 | 2025-03-20 | Sarepta Therapeutics Inc | Conjugados oligonucleótido-péptido. |
| RU2724554C2 (ru) | 2015-09-15 | 2020-06-23 | Ниппон Синяку Ко., Лтд. | Антисмысловая нуклеиновая кислота |
| WO2017059131A1 (en) * | 2015-09-30 | 2017-04-06 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
| BR112018007066A2 (pt) | 2015-10-09 | 2018-10-23 | Sarepta Therapeutics Inc | composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados |
| JP7511326B2 (ja) | 2015-10-09 | 2024-07-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物およびその方法 |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017095967A2 (en) * | 2015-11-30 | 2017-06-08 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| CN108472504A (zh) * | 2015-12-15 | 2018-08-31 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| MA45183A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| EP3464305B1 (en) | 2016-05-24 | 2024-08-21 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| CN109311920B (zh) | 2016-05-24 | 2021-11-09 | 萨勒普塔医疗公司 | 制备磷酸二酰胺吗啉代寡聚物的方法 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| KR20190009343A (ko) * | 2016-05-24 | 2019-01-28 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 에테플리센을 포함하는 약제학적 조성물 |
| JP2019525742A (ja) * | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| CN106581043A (zh) * | 2016-10-24 | 2017-04-26 | 佳木斯大学 | 一种适用于杜氏肌营养不良症的药物制剂及其制备方法 |
| EP3545090A1 (en) * | 2016-11-28 | 2019-10-02 | The Board of Regents of The University of Texas System | Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing |
| KR20240006023A (ko) * | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| EP3554553B1 (en) * | 2016-12-19 | 2022-07-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3047010A1 (en) * | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| KR20190104381A (ko) | 2017-01-06 | 2019-09-09 | 어비디티 바이오사이언시스 엘엘씨 | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| WO2018236879A1 (en) | 2017-06-19 | 2018-12-27 | University Of Maryland, Baltimore | Microtubule polymerization inhibitor prodrugs and methods of using the same |
| EP3655534B1 (en) | 2017-07-18 | 2025-07-16 | CSL Behring Gene Therapy, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019046755A1 (en) * | 2017-08-31 | 2019-03-07 | Sarepta Therapeutics, Inc. | METHODS FOR TREATING MUSCLE DYSTROPHY |
| KR20250065737A (ko) * | 2017-09-22 | 2025-05-13 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
| US20200248178A1 (en) * | 2017-09-28 | 2020-08-06 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| EA202091828A1 (ru) * | 2018-01-31 | 2021-05-24 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Композиции и способы коррекции мутаций дистрофина в кардиомиоцитах человека |
| EP3765030A4 (en) | 2018-03-16 | 2022-01-26 | Sarepta Therapeutics, Inc. | CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION |
| WO2019209764A2 (en) * | 2018-04-26 | 2019-10-31 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP4219717A3 (en) * | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| WO2019241385A2 (en) * | 2018-06-13 | 2019-12-19 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystropy |
| JP7345466B2 (ja) | 2018-06-26 | 2023-09-15 | 日本新薬株式会社 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| SG11202100934PA (en) * | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2022514955A (ja) | 2018-12-23 | 2022-02-16 | シーエスエル・ベーリング・エルエルシー | ウィスコット・アルドリッチ症候群の造血幹細胞遺伝子治療 |
| EP3897831A1 (en) | 2018-12-23 | 2021-10-27 | CSL Behring LLC | Donor t-cells with kill switch |
| WO2020157760A1 (en) | 2019-01-31 | 2020-08-06 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| CA3134165A1 (en) * | 2019-03-28 | 2020-10-01 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy with casimersen |
| JP2022528725A (ja) * | 2019-04-18 | 2022-06-15 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを治療するための組成物 |
| AU2020263487A1 (en) | 2019-04-25 | 2021-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| JP2022536495A (ja) * | 2019-06-19 | 2022-08-17 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを治療する方法 |
| US20220282247A1 (en) * | 2019-08-02 | 2022-09-08 | Research Institute At Nationwide Children's Hospital | Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies |
| JP7706450B2 (ja) * | 2019-10-30 | 2025-07-11 | 武田薬品工業株式会社 | オリゴヌクレオチドを検出するための方法 |
| CN118109469A (zh) * | 2019-12-26 | 2024-05-31 | 日本新药株式会社 | 诱导外显子50的跳读的反义核酸 |
| CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| CA3187301A1 (en) * | 2020-06-17 | 2021-12-23 | Stealth Biotherapeutics Inc. | Methods and compositions for the treatment of muscular dystrophy |
| CN115997015A (zh) | 2020-06-26 | 2023-04-21 | 美国杰特贝林生物制品有限公司 | 具有杀伤开关的供体t细胞 |
| MX2024000489A (es) | 2021-07-09 | 2024-04-09 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías. |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| IL311507A (en) * | 2021-09-16 | 2024-05-01 | Dyne Therapeutics Inc | Dosing of muscle targeting complexes for the treatment of dystrophinopathy |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20250066396A1 (en) | 2021-12-27 | 2025-02-27 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20250195667A1 (en) * | 2022-03-17 | 2025-06-19 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| JP2025524469A (ja) | 2022-06-24 | 2025-07-30 | チューン セラピューティクス インコーポレイテッド | 標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法 |
| CN115820642B (zh) * | 2022-11-11 | 2023-10-10 | 昆明理工大学 | 一种用于治疗杜氏肌营养不良症的CRISPR-Cas9系统 |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0215942B1 (en) | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US5869252A (en) | 1992-03-31 | 1999-02-09 | Abbott Laboratories | Method of multiplex ligase chain reaction |
| EP0633944B1 (en) | 1992-03-31 | 2000-11-08 | Abbott Laboratories | Method of multiplex ligase chain reaction |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| AU6786594A (en) | 1993-05-11 | 1994-12-12 | University Of North Carolina At Chapel Hill, The | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| GB9510718D0 (en) | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| CA2749312A1 (en) | 1996-02-14 | 1997-08-21 | Novartis Ag | Sugar-modified gapped oligonucleotides |
| AU2585197A (en) | 1996-03-20 | 1997-10-10 | Regents Of The University Of California, The | Antisense approach to gene inhibition |
| US6153436A (en) | 1997-01-10 | 2000-11-28 | The Board Of Trustees Of The University Of Arkansas | Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US20030114401A1 (en) | 2001-12-06 | 2003-06-19 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-1 expression |
| GB9819999D0 (en) | 1998-09-14 | 1998-11-04 | Univ London | Treatment of cancer |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| WO2000028980A2 (en) | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| WO2000045167A2 (en) | 1999-01-29 | 2000-08-03 | Avi Biopharma, Inc. | Non-invasive method for detecting target rna |
| US20020049173A1 (en) | 1999-03-26 | 2002-04-25 | Bennett C. Frank | Alteration of cellular behavior by antisense modulation of mRNA processing |
| JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| AU768904B2 (en) | 1999-06-21 | 2004-01-08 | Murdoch Childrens Research Institute, The | A method for the prophylaxis and/or treatment of medical disorders |
| EP1242052A4 (en) | 1999-12-29 | 2003-07-02 | A James Mixson | HISTIDIN COPOLYMER AND METHODS OF USE THEREOF |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| AU781676B2 (en) | 2000-01-04 | 2005-06-02 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| WO2001072765A1 (en) | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
| US6653467B1 (en) | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| CN100422320C (zh) | 2000-04-28 | 2008-10-01 | 肖啸 | 编码抗肌萎缩蛋白小基因的dna序列及其使用方法 |
| AU2001257366B2 (en) | 2000-05-01 | 2006-03-16 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| KR20020097241A (ko) | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| JP4836366B2 (ja) | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| DE60119173T2 (de) | 2000-08-30 | 2007-01-18 | Avi Biopharma, Inc., Corvallis | Methode zur analyse von oligonukleotidanaloga |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| AU2001289085A1 (en) | 2000-09-20 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of flip-c expression |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| US6689615B1 (en) | 2000-10-04 | 2004-02-10 | James Murto | Methods and devices for processing blood samples |
| JP3781687B2 (ja) | 2001-02-23 | 2006-05-31 | 松下電器産業株式会社 | 遺伝子診断装置及び遺伝子診断方法 |
| US6656732B1 (en) | 2001-05-18 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of src-c expression |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7250289B2 (en) | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| US7314750B2 (en) | 2002-11-20 | 2008-01-01 | Affymetrix, Inc. | Addressable oligonucleotide array of the rat genome |
| CA2942791C (en) | 2002-11-25 | 2019-08-20 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| ES2351976T3 (es) | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
| RU2322261C2 (ru) * | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| EP1495769B1 (en) | 2003-07-11 | 2008-02-27 | LBR Medbiotech B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| ATE491791T1 (de) | 2003-08-05 | 2011-01-15 | Avi Biopharma Inc | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen |
| US20050048495A1 (en) | 2003-08-29 | 2005-03-03 | Baker Brenda F. | Isoform-specific targeting of splice variants |
| US20050153935A1 (en) | 2003-09-12 | 2005-07-14 | Iversen Patrick L. | Compound and method for treating androgen-independent prostate cancer |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| NO20051491L (no) | 2005-03-21 | 2006-09-22 | Norsk Hydro As | Fremgangsmate og anordning ved en gravitasjonsseparator. |
| KR20080031164A (ko) | 2005-04-22 | 2008-04-08 | 아카데미슈 지켄후이스 라이덴 | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| JP2009515523A (ja) | 2005-11-10 | 2009-04-16 | サンタリス ファーマ アー／エス | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 |
| US20090011004A1 (en) | 2005-12-30 | 2009-01-08 | Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
| GB0602767D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US7943762B2 (en) | 2006-05-10 | 2011-05-17 | Avi Biopharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| US20070265215A1 (en) | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009101399A1 (en) | 2008-02-12 | 2009-08-20 | Isis Innovation Limited | Treatment of muscular dystrophy using peptide nucleic acid ( pna) |
| PL2108366T3 (pl) * | 2008-04-09 | 2012-03-30 | Santhera Pharmaceuticals Schweiz Ag | Idebenon stosowany w leczeniu chorób układu oddechowego towarzyszących dystrofii mięśniowej |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| TR201902952T4 (tr) | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| PT2344637E (pt) | 2008-10-27 | 2015-03-23 | Academisch Ziekenhuis Leiden | Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne |
| WO2010080554A1 (en) | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| CN102625840A (zh) | 2009-04-10 | 2012-08-01 | 肌肉学研究协会 | 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法 |
| JP2012524540A (ja) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー．ブイ． | Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド |
| EP2258863A1 (en) | 2009-05-25 | 2010-12-08 | Universita'Degli Studi di Roma "La Sapienza" | miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics |
| DK2435583T3 (da) | 2009-05-25 | 2014-09-29 | Universit Degli Studi Di Roma La Sapienza | miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI |
| ITTO20090487A1 (it) | 2009-06-26 | 2010-12-27 | Univ Ferrara | Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd) |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2473607A2 (en) | 2009-08-31 | 2012-07-11 | INSERM - Institut National de la Santé et de la Recherche Médicale | Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy |
| IT1397011B1 (it) | 2009-10-14 | 2012-12-20 | Univ Ferrara | Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| CA2799501C (en) | 2010-05-28 | 2022-02-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| CN103096928A (zh) | 2010-06-28 | 2013-05-08 | 萩原正敏 | 遗传性疾病的预防/改善剂 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| JP5831455B2 (ja) | 2010-09-30 | 2015-12-09 | 日本新薬株式会社 | モルホリノ核酸誘導体 |
| JP2014507143A (ja) | 2011-02-08 | 2014-03-27 | ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム | アンチセンスオリゴヌクレオチド |
| KR102229650B1 (ko) | 2011-05-05 | 2021-03-19 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP2750715B1 (en) | 2011-08-30 | 2018-10-31 | The Regents of The University of California | Identification of small molecules that enhance therapeutic exon skipping |
| US20140080896A1 (en) | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
| SMT201900337T1 (it) * | 2011-09-05 | 2019-07-11 | Mitsubishi Tanabe Pharma Corp | Agente medicinale per trattare la sclerosi laterale amiotrofica o prevenire la progressione di una fase della sclerosi laterale amiotrofica |
| EP2581448B1 (en) | 2011-10-13 | 2015-01-28 | Association Institut de Myologie | Tricyclo-phosphorothioate DNA |
| IN2014DN06220A (enExample) | 2011-12-28 | 2015-10-23 | Nippon Shinyaku Co Ltd | |
| CN111893117B (zh) | 2012-01-27 | 2024-06-04 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| EP2828395B1 (en) | 2012-03-20 | 2018-10-24 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| RU2674600C2 (ru) | 2012-07-03 | 2018-12-11 | Просенса Текнолоджиз Б.В. | Олигонуклеотид для лечения пациентов с мышечной дистрофией |
| BR112015014987A2 (pt) | 2012-12-20 | 2017-08-15 | Sarepta Therapeutics Inc | Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| SMT201900139T1 (it) | 2013-03-14 | 2019-05-10 | Sarepta Therapeutics Inc | Composizioni di salto dell'esone per il trattamento della distrofia muscolare |
| MX373959B (es) | 2013-03-15 | 2020-07-13 | Sarepta Therapeutics Inc | Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd). |
| WO2014172669A1 (en) | 2013-04-20 | 2014-10-23 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
| KR102733409B1 (ko) * | 2013-06-05 | 2024-11-21 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| WO2017059131A1 (en) | 2015-09-30 | 2017-04-06 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
| JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
-
2014
- 2014-03-14 MX MX2015013117A patent/MX373959B/es active IP Right Grant
- 2014-03-14 CA CA2906812A patent/CA2906812A1/en active Pending
- 2014-03-14 US US14/214,567 patent/US9506058B2/en active Active
- 2014-03-14 KR KR1020157029546A patent/KR20150133768A/ko not_active Ceased
- 2014-03-14 NZ NZ732507A patent/NZ732507A/en unknown
- 2014-03-14 JP JP2016503163A patent/JP2016516066A/ja not_active Withdrawn
- 2014-03-14 HK HK16108175.2A patent/HK1220154A1/zh unknown
- 2014-03-14 AU AU2014233456A patent/AU2014233456B2/en active Active
- 2014-03-14 CN CN202110759294.6A patent/CN113633787A/zh active Pending
- 2014-03-14 US US14/213,629 patent/US20140329762A1/en not_active Abandoned
- 2014-03-14 EA EA201591792A patent/EA201591792A1/ru unknown
- 2014-03-14 WO PCT/US2014/029610 patent/WO2014144978A2/en not_active Ceased
- 2014-03-14 NZ NZ631289A patent/NZ631289A/en unknown
- 2014-03-14 KR KR1020207034743A patent/KR20200139271A/ko not_active Ceased
- 2014-03-14 CN CN201480026195.5A patent/CN105307723A/zh active Pending
- 2014-03-14 EP EP19207586.9A patent/EP3662912B1/en active Active
- 2014-03-14 BR BR112015022998A patent/BR112015022998A2/pt not_active Application Discontinuation
- 2014-03-14 EP EP14722043.8A patent/EP2968991A2/en not_active Withdrawn
-
2015
- 2015-09-10 IL IL24155815A patent/IL241558B/en active IP Right Grant
- 2015-09-15 MX MX2020004986A patent/MX2020004986A/es unknown
-
2016
- 2016-11-22 US US15/359,152 patent/US10337003B2/en active Active
-
2017
- 2017-05-24 US US15/604,335 patent/US10364431B2/en active Active
-
2019
- 2019-02-22 JP JP2019030772A patent/JP2019108349A/ja active Pending
- 2019-05-20 AU AU2019203505A patent/AU2019203505A1/en not_active Abandoned
- 2019-05-24 US US16/422,241 patent/US20190359982A1/en not_active Abandoned
- 2019-06-07 US US16/434,799 patent/US20200040337A1/en not_active Abandoned
- 2019-10-06 IL IL26984519A patent/IL269845A/en unknown
-
2020
- 2020-10-29 AU AU2020260492A patent/AU2020260492A1/en not_active Abandoned
- 2020-11-23 IL IL278912A patent/IL278912A/en unknown
-
2021
- 2021-10-21 US US17/506,846 patent/US20220033820A1/en not_active Abandoned
-
2022
- 2022-01-03 US US17/567,252 patent/US20220403385A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278912A (en) | Improved preparations for the treatment of muscular dystrophy | |
| IL272415A (en) | Preparations that skip axon for the treatment of muscular dystrophy | |
| IL240984A0 (en) | Preparations that skip axon for the treatment of muscular dystrophy | |
| SI2984166T1 (sl) | Sestavki za zdravljenje MPSI | |
| ZA201508106B (en) | Novel nanoparticle compositions | |
| GB201304662D0 (en) | Compositions | |
| GB201319525D0 (en) | Composition | |
| GB201313615D0 (en) | Compositions | |
| GB201318489D0 (en) | Composition | |
| GB201319540D0 (en) | Composition | |
| GB201320919D0 (en) | Composition | |
| GB201317388D0 (en) | Composition | |
| GB201320303D0 (en) | Composition | |
| GB201319538D0 (en) | Composition | |
| GB201306984D0 (en) | Composition | |
| PL2968226T3 (pl) | Kompozycje oksprenololu do leczenia raka | |
| GB201317196D0 (en) | Composition | |
| GB201320962D0 (en) | Compositions | |
| GB201415000D0 (en) | Improved process | |
| GB201320504D0 (en) | Composition | |
| GB201308502D0 (en) | Composition | |
| GB201301774D0 (en) | Composition | |
| GB201320959D0 (en) | Compositions | |
| GB201320675D0 (en) | Composition | |
| GB201312224D0 (en) | Compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |